Educational Opportunities for Providers
Cure SMA is committed to supporting healthcare providers. Our educational programs aim to serve as a resource for clinicians and ensure the availability of useful, timely, and accurate information about spinal muscular atrophy (SMA).
Enduring CME Events
Best Practices in the Care of Adult Patients with Spinal Muscular Atrophy
Credits Available:
- Physicians – maximum of 0.50 AMA PRA Category 1 Credit(s)™
- ABIM Diplomates – maximum of 0.50 ABIM MOC points
- Nurses – 0.50 ANCC Contact Hour(s) (0.25 contact hours are in the area of pharmacology)
- IPCE – 0.25 Interprofessional Continuing Education (IPCE) credit
Estimated Time to Complete Activity: 30 minutes
Available through January 20, 2024.
Check back for upcoming educational opportunities!
Additional CME opportunity coming soon.
Additional CME opportunity coming soon.
Non-Credit Opportunities
Cure SMA partnered with Platform Q to develop six modules covering support and care for children with SMA after gene replacement therapy. These modules showcase the family perspective on gene therapy and multidisciplinary care for SMA.
Cure SMA partnered with Platform Q to develop six modules covering support and care for children with SMA after gene replacement therapy. These modules showcase the family perspective on gene therapy and multidisciplinary care for SMA.
Module 1: Understanding Gene Replacement Therapy in SMA
Module 2: Life After SMA Gene Replacement Therapy
Module 3: Respiratory Care and SMA
Module 4: Rehabilitative Care and SMA
Module 5: Nutrition and SMA
Module 6: Shared Stories of SMA Families - The Good, Bad and In Between
Cure SMA’s Virtual Summit of Strength Webinars and 2020 Virtual SMA Conference Webinars provide a variety of educational topics on SMA. These are posted on our YouTube channel and available to the public. There is no CE/CME credit associated with these videos.
In 2016, experts in SMA care met to present and discuss the latest discoveries and options for optimizing care. The meeting was organized by Penn Medicine of The University of Pennsylvania’s and was co-sponsored by Novartis Gene Therapies (formerly AveXis) and the Orphan Disease Center.